Robert Schickel
Co-Founder, Chief Executive Officer, NUAgo Therapeutics
Graduation Year:
2009
Thesis:
The Characterization of Fas Non-apoptotic Signaling and Identification of miR-200c as a regulator of Fas Signaling
Advisor:
Peter Marcus